These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

Source The Motley Fool

Key Points

  • AbbVie, Gilead, and Becton, Dickinson have all beaten the S&P 500 this year.

  • Two are Dividend Kings, and Gilead has raised its payout by 74.5% over the past decade.

  • 10 stocks we like better than AbbVie ›

Artificial intelligence (AI) stocks continue dominating headlines on Wall Street. That probably won't change anytime soon. But investors shouldn't be so distracted by the AI revolution that they forget there are attractive investment opportunities elsewhere. Consider the following three healthcare dividend stocks: AbbVie (NYSE:ABBV), Gilead Sciences (NASDAQ:GILD), and Becton, Dickinson (NYSE:BDX). All three have crushed broader equities this year, and they still have plenty of upside ahead for investors willing to stay the course. Read on to find out more.

Scientist using a pipette to prepare samples at a laboratory bench

Image source: Getty Images.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

1. AbbVie

AbbVie did not perform well in the first four months of the year, but it has recovered, and its shares are now up 29% to date, while the S&P 500 has gained 10%. There are several reasons behind the drugmaker's strong performance, perhaps none more important than its two biggest growth drivers, Skyrizi and Rinvoq. These two immunology medicines are performing better than management -- and Wall Street -- expected.

Considering they won't lose patent protection anytime soon, and AbbVie will face no other major loss of patent exclusivity through the end of this decade, we can expect consistent revenue and earnings growth over the medium term. Still, Skyrizi and Rinvoq will eventually face patent cliffs, with the former perhaps starting around 2033. The good news is AbbVie is preparing for that.

AbbVie has strengthened its immunology pipeline through an acquisition and is looking to enter the fast-growing weight-loss market. Further, legacy products, especially its Botox franchise, should perform well over the long term. AbbVie's excellent underlying business will help support its dividend program.

The company is a Dividend King, one of the corporations that have increased their payouts for at least 50 consecutive years. It would take something catastrophic for AbbVie to suspend or decrease its dividends. Until then, expect regular dividend increases alongside solid returns from the company.

2. Gilead Sciences

Gilead Sciences' shares have gained 37% this year on the back of improving financial results and solid clinical and regulatory progress. The biotech leader still makes most of its money from its HIV franchise, with medicines like Biktarvy doing much of the heavy lifting. And even though Veklury, a coronavirus medicine, is harming top-line growth, the company has performed well.

Gilead Sciences' third-quarter product sales grew 13% year over year -- its fastest growth rate in this category in over a decade -- to $8.29 billion. Total revenue was $8.30 billion, up almost 7% compared to the year-ago period. Product sales excluding Veklury jumped 16% year over year.

So, as Veklury continues to fade into insignificance, Gilead should record stronger top-line growth, especially as it has strengthened its HIV and oncology businesses this year with new approvals and important label expansions. The biotech giant's outlook appears stronger than it has been in a while, and its dividend program remains attractive. Gilead Sciences offers a forward yield of 2%, and it has increased its payouts by 74.5% over the past 10 years.

3. Becton, Dickinson

Becton, Dickinson, a medical technology company, is finally bouncing back after several challenging years. Shares are up 43% to date. One reason for the company's strong performance is its excellent financial results. In the fourth quarter of its fiscal year 2026, which ended Sept. 30, Becton, Dickinson's revenue increased by 5.4% year over year to $5.3 billion. Adjusted earnings per share rose 27.3% year over year to $4.15.

That's a strong performance for the healthcare giant. Another factor behind Becton, Dickinson's results is that it is benefiting from the soaring demand for GLP-1 products and should continue to do so over the medium term.

Growing demand for injectable diabetes and weight-loss medicines is driving significant increases in sales of prefillable syringes and self-injection devices for GLP-1 drugs. With the GLP-1 market projected to expand rapidly over the next five to 10 years, this tailwind may be just starting for Becton, Dickinson.

Meanwhile, the company's underlying business outside of that is resilient and highly predictable. Becton, Dickinson generates most of its revenue from recurring consumables. Finally, Becton, Dickinson is an excellent dividend stock. It is also a Dividend King with a streak of 55 consecutive payout increases.

Should you buy stock in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 16, 2026.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Gilead Sciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
Author  Irene Q.
22 hours ago
Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
21 hours ago
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
Author  Irene Q.
21 hours ago
The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
21 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
20 hours ago
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
goTop
quote